Payload Information
General Information of This Payload
| Payload ID | PAY0YCQYO |
|||||
|---|---|---|---|---|---|---|
| Name | Topo1 inhibitor D |
|||||
| Synonyms |
Topo1 inhibitor D
Click to Show/Hide
|
|||||
| Target | DNA topoisomerase I (TOP1) | |||||
| Structure |
|
|||||
| Formula | C25H23N3O5 |
|||||
| Isosmiles | CC[C@]1(O)C(C=C2C3=C(CN24)C(CN5C(CCC5)=O)=C6C=CC=CC6=N3)=C(COC1=O)C4=O |
|||||
| InChI |
InChI=1S/C25H23N3O5/c1-2-25(32)18-10-20-22-16(12-28(20)23(30)17(18)13-33-24(25)31)15(11-27-9-5-8-21(27)29)14-6-3-4-7-19(14)26-22/h3-4,6-7,10,32H,2,5,8-9,11-13H2,1H3/t25-/m0/s1
|
|||||
| InChIKey |
TWQWSSOJWGYYLM-VWLOTQADSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
445.475 |
Polar area |
101.73 |
||
Complexity |
1391.786015 |
xlogp Value |
2.202 |
|||
Heavy Count |
33 |
Rot Bonds |
3 |
|||
Hbond acc |
7 |
Hbond Donor |
1 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
CN112341521B+ADC-5 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC54) |
20.44 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (54%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | HCC-827 cells | CVCL_2063 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC53) |
1181 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (53%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1975 cells | CVCL_1511 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC52) |
64.44 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (52%% inhibitory concentration).
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1650 cells | CVCL_1483 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC51) |
25.96 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (51%% inhibitory concentration).
|
||||
| In Vitro Model | Squamous cell carcinoma of the oral tongue, Tongue squamous cell carcinoma | CAL33 cells | CVCL_1108 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.69 ug/mL
|
|||
| Method Description |
Add the antibody-coupled drug product C or nimotuzumab with a specified concentration to the cells, incubate for 3 days, and then add 40uL of Promega CellTiter-Glo reagent (Promega catalog number G968B). Subsequently, the chemiluminescence reading from CellTiter-Glo reagent was read to determine IC50 (50%% inhibitory concentration).
|
||||
| In Vitro Model | Hypopharyngeal squamous cell carcinoma | FaDu cells | CVCL_1218 | ||
References